Reduce steroid in long-term use of Dupixent in asthmatic pts

Sanofi releases three-year data on Dupixent for severe asthma patients

81% improvement in annual morbidity of steroid dependent patients

Reduce steroid use by more than 70%

Sanofi's Dupixent was found to improve major symptoms in a three-year long-term follow-up of severe asthma patients while reducing the use of oral corticosteroids.

 

The results of these studies were released at the 2022 ERS Annual Academic Conference held from the 4th to the 6th.

 

Through this conference, Dupixent released a number of data and RWE data confirming the improvement effect of asthma symptoms related to type 2 inflammatory biomarkers to solidify the treatment effect and safety profile in type 2 inflammatory severe asthma.

 

It proved that it is a treatment that reduces the frequency of deterioration of severe asthma and lowers the severity, thereby helping to reach the treatment goal of severe asthma.

 

Post-analysis study data from VENTURE/TRAVERSE clinical trials once again suggested that Dupixent could be a treatment solution for severe asthma patients, including Steroid-dependent patients.

 

According to published data, Dupixent reduced steroid use for three years while improving major symptoms of asthma, including severe annual exacerbation and lung function deterioration.

 

The results of this post-analysis study were conducted on Steroid-dependent asthma patients who participated in the VENTURE study, the existing phase 3 clinical trial of Dupixent.

 

Patients who were administered Dupixent 300 mg or placebo every two weeks in the existing VENTURE clinical trial received additional Dupixent for up to 96 weeks through TRAVERSE clinical trials.

 

These patients were analyzed by dividing them into patients who used Steroids less than or equal to 10 mg per day.

 

If the daily usage exceeds 10 mg, caution is needed as it can be exposed to steroid side effects such as diabetes and osteoporosis in the long run.

 

According to the main results, Dupixent decreased the annual severe asthma exacerbation rate of patients regardless of Steroid use at 96 weeks from the end of the previous study, VEUNTURE.

 

Among patients with daily Steroid use exceeding 10 mg, the placebo-administered group showed an improvement of more than 81% in the annual severe asthma exacerbation rate at 96 weeks of Dupixent administration.

 

It was also found to have improved by more than 43% in the existing Dupixent administration group, confirming the effect of Dupixent in Steroid-dependent asthma patients.

 

In the group of patients with daily steroid use of 10mg or less, it was found to have improved by more than 80% and 36%, respectively, compared to the baseline of the VENTURE study.

 

Steroid use also decreased as asthma symptoms improved with Dupixent.

 

Dupixent reduced Steroid use by more than 70% at 96 weeks of administration, regardless of both Dupixent/ placebo administration and Steroid use compared to the baseline of the VENTURE study.

 

Patients with daily steroid use exceeding 10 mg also decreased by 83%, confirming the long-term treatment effect of Dupixent in Steroid-dependent patients.

 

The data released on that day also included RWE data from the United States analyzed for severe asthma patients who received Dupixent.

 

According to the data, Dupixent reduced the rate of emergency room visits related to asthma by up to 73.4%, and the rate of hospitalization by up to 66.7%.

 

In addition, it has been confirmed that medical expenses related to asthma have been reduced by reducing the frequency of visits to internal medicine.